Browse > Article
http://dx.doi.org/10.3746/jkfn.2014.43.1.040

The Hepatoprotective Effect of Acanthopanax senticosus Fermentation Products in Fatty Liver Model  

Cho, Ju-Hyun (Hurum Central Research Institute Co., Ltd.)
Park, In-Jae (Hurum Central Research Institute Co., Ltd.)
Choi, Soo-Young (College of Biology, Chungbuk National University)
Baik, Soon-Ok (Hurum Central Research Institute Co., Ltd.)
Kim, Choong-Sik (Hurum Central Research Institute Co., Ltd.)
Publication Information
Journal of the Korean Society of Food Science and Nutrition / v.43, no.1, 2014 , pp. 40-46 More about this Journal
Abstract
We demonstrated that Acanthopanax senticosus fermentation products (FM-5111 and FM-5131) administered to rats functionally protect against DL-ethionine-induced and ethanol-induced fatty liver models. In DL-ethionine-induced fatty liver models, the serum concentrations of aspartate aminotransferase (AST), as well as liver concentrations of triglyceride and total lipid against the control decreased in FM-5111 and FM-5131 treated rats. In ethanol-induced fatty liver models, FM-5111 and FM-5131 treated rats showed a decrease in the liver concentrations of triglyceride and total lipid in ethanol-induced fatty liver models. There were no significant differences in the serum concentrations of AST and alanine aminotransferase in FM-5111 and FM-5131 treated rats. Additionally, FM-5111-, or FM-5131-treated rats showed no significant differences in the body weight gain between the control. These results indicate that Acanthopanax senticosus fermentation products might have protective effects against DL-ethionine-induced and ethanol-induced fatty liver models.
Keywords
Acanthopanax senticosus fermentation; DL-ethionine-induced fatty liver model; ethanol-induced fatty liver model; Ganoderma lucidum; Phellinus linteus;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Purohit V, Russo D, Coates PM. 2004. Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium. Alcohol 34: 3-8.   DOI   ScienceOn
2 Younossi ZM. 1999. Nonalcoholic fatty liver disease. Curr Gastroenterol Rep 1: 57-62.   DOI   ScienceOn
3 Stewart S, Jones D, Day CP. 2001. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 7: 408-413.   DOI   ScienceOn
4 Mallov S, Bloch JL. 1956. Role of hypophysis and adrenals in fatty infiltration of liver resulting from acute ethanol intoxication. Am J Physiol 184: 29-34.
5 Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. 2002. Is NASH underdiagnosed among African Americans? Am J Gastroenterol 97: 1496-1500.   DOI
6 Lieber CS. 2004. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 34: 9-19.   DOI   ScienceOn
7 Lakshman MR. 2004. Some novel insights into the pathogenesis of alcoholic steatosis. Alcohol 34: 45-48.   DOI   ScienceOn
8 Papatheodoridis GV, Chrysanthos N, Cholongitas E, Pavlou E, Apergis G, Tiniakos DG, Andrioti E, Theodossiades G, Archimandritis AJ. 2009. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J Hepatol 51: 931-938.   DOI   ScienceOn
9 Bijl N, Sokolović M, Vrins C, Langeveld M, Moerland PD, Ottenhoff R, van Roomen CP, Claessen N, Boot RG, Aten J, Groen AK, Aerts JM, van Eijk M. 2009. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology 50: 1431-1441.   DOI   ScienceOn
10 Mehta K, Van Thiel DH, Shah N, Mobarhan S. 2002. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 60: 289-293.   DOI   ScienceOn
11 Duvnjak M, Lerotic I, Barsic N, Tomasic V, Virovic Jukic L, Velagic V. 2007. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 13: 4539-4550.
12 Brekhman II. 1960. A new medicinal plant of the family Araliaceae the spiny Eleutherococcus. Izv Sibir Otdel Akad Nauk USSR 9: 113-120.
13 Lee KH, Jeong H, Kim YI, Kim BK. 1991. Production of antihypertensive constituents from Ganoderma lucidum IY005 by fermentation using industrial wastes. Korean J Mycol 19: 79-84.   과학기술학회마을
14 Ovodov YS, Ovodova RG, Solov'eva TF, Elyakov GB, Kochetkov NK. 1965. The glycosides of Eleutherococcus senticosus Max. I. Isolation and some properties of eleutheroside B and E. Khim Prir Soedin 1: 1-4.
15 Halstead BW, Hood LL. 1984. An introduction to adaptogenic medicine. In Eleutherococcus senticosus: Siberian ginseng. Origental Healing Arts Institute, Bristol, CT, USA. p 1-94.
16 Hirata F, Fujita K, Ishikura Y, Hosoda K, Ishikawa H, Nakamura H. 1996. Hypocholesterolemic effect of sesame lignan in humans. Atherosclerosis 122: 135-136.   DOI   ScienceOn
17 Uchiyama M, Mihara M. 1978. Determination of malondialdehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86: 271-278.   DOI   ScienceOn
18 Oh SI, Lee MS. 2005. Antioxidative and antimutagenic effects of Ganoderma lucidum krast extracts. Korean J Food & Nutr 18: 54-62.   과학기술학회마을
19 Bae HS, Kang SK, Shin IS, Woo SK, Kim YJ, Kim MA, Ra JC. 2009. The effects of extracts mixture drink from Inonotus obliquus, Phellinus linteus and Ganoderma lucidum on hematopoietic stem cells and lymphocyte subset of blood in human. J Fd Hyg Safety 24: 78-85.   과학기술학회마을
20 Lee SY, Rhee HM. 1990. Cardiovascular effects of mycelium extract of Ganoderma lucidum: inhibition of sympathetic outflow as a mechanism of its hypotensive action. Chem Pharm Bull 38: 1359-1364.   DOI   ScienceOn
21 Usui T, Iwasaki Y, Hayashi K, Mizuno T, Tanaka M, Shinkai K, Arakawa M. 1981. Antitumor activity of water-soluble beta-D-glucan elaborated by Ganoderma applanatum. Agric Biol Chem 45: 323-326.   DOI
22 Sone Y, Okuda R, Wada N, Kishida E, Misaki A. 1985. Structures and antitumor activities of the polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganoderma lucidum. Agric Biol Chem 49: 2641-2653.   DOI
23 Frings CS, Dunn RT. 1970. A colorimetric method for determination of total serum lipids based on the sulfo-phospho-vanilin reaction. Am J Clin Pathol 53: 89-91.
24 Suriawinate AA, Thung SN. 2006. Acute and chronic hepatitis. Seminars in Diagnostic Pathology 23: 132-148.   DOI   ScienceOn
25 Canbay A, Bechmann L, Gerken G. 2007. Lipid metabolism in the liver. Z Gastroenterol 41: 35-41.
26 Wang J, Atchison RW, Walpusk J, Jaffe R. 2001. Echovirus hepatic failure in infancy: report of four cases with speculation on the pathogenesis. Pediatr Dev Pathol 4: 454-460.   DOI
27 Mira L, Maia L, Barreira L, Manso CF. 1995. Evidence for free radical generationdue to NADH oxidation by aldehyde oxidase during ethanol metabolism. Arch Biochem Biophys 318: 53-58.   DOI   ScienceOn
28 Adams LA, Angulo P. 2005. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 22: 1129-1133.   DOI   ScienceOn
29 Ko JS, Yoon JM, Yang HR, Myung JK, Kim H, Kang GH, Cheon JE, Seo JK. 2009. Clinical and histological features of nonalcoholic fatty liver disease in children. Dig Dis Sci 54: 2225-2230.   DOI   ScienceOn
30 Salgado Júnior W, Santos JS, Sankarankutty AK, de Castro e Silva O. 2006. Nonalcoholic fatty liver disease and obesity. Acta Cir Bras 21 (suppl. 1): 72-78.   DOI   ScienceOn
31 Adachi Y, Ohno N, Ohsawa M, Oikawa S, Yadomae T. 1990. Macrophage activation in vitro by chemically crosslinked (1$\rightarrow$3)-beta-D-glucans. Chem Pharm Bull 38: 988-992.   DOI   ScienceOn